Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WCC promotes chief medical officer to president
As president, Walovitch will continue to provide medical leadership for the entire organisation. He will also be responsible for directing the operations, regulatory, sales and marketing activities and
As president, Walovitch will continue to provide medical leadership for the entire organisation. He will also be responsible for directing the operations, regulatory, sales and marketing activities and
Bailey will replace David Rosenthal, who has served as interim president and CEO since 27 February 2010. Rosenthal said that they were pleased that Bailey has chosen to
China Medicine has posted a net income of $2.22m for the third quarter 2010, or $0.06 per diluted share, compared to a net income of $3.22m, or $0.21
The collaboration combines Bend Research’s advanced drug formulation capabilities and Quotient Clinical’s clinical-trial design service, RapidFACT (Rapid Formulation development And Clinical Testing). RapidFACT represents a new paradigm for
ProPhase Labs has posted a net loss of $947,000 for the third quarter 2010, or $0.06 loss per diluted share, compared to net loss of $1.2m, or $0.09
SuperGen said that the dose limiting toxicity of cardiac QTc prolongation was identified previously in the Phase 1 study in patients with refractory prostate and lymphoma. Additional detailed
Nuvo is primarily focused on the R&D of drug products delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development
The IntegenX programs focus on developing platforms for DNA sample preparation, sequencing library preparation and sample-to-answer analysis of human genotypes. IntegenX president and CEO Stevan Jovanovich said that
In January this year Novartis had agreed to invest $24m to secure access to chip-in-a-pill technology developed by California-based privately held firm Proteus Biomedical, Reuters reported. The embedded
The winds of change seem fairly constant in the pharmaceutical industry. Complex legislative and regulatory issues, increased competition, complex company structures, and mergers and acquisitions all impact on